Victory Capital Management Inc. trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 91.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,023 shares of the biotechnology company’s stock after selling 174,338 shares during the quarter. Victory Capital Management Inc.’s holdings in Blueprint Medicines were worth $1,398,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP acquired a new position in shares of Blueprint Medicines during the third quarter worth about $32,000. R Squared Ltd purchased a new stake in Blueprint Medicines during the fourth quarter worth about $51,000. Asset Management One Co. Ltd. purchased a new stake in Blueprint Medicines during the fourth quarter worth about $88,000. Van ECK Associates Corp boosted its holdings in Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after buying an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Blueprint Medicines during the third quarter worth about $108,000.
Insider Buying and Selling
In related news, Director Jeffrey W. Albers sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares of the company’s stock, valued at approximately $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company’s stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,334 shares of company stock valued at $4,450,062. Insiders own 4.21% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on BPMC
Blueprint Medicines Stock Performance
NASDAQ:BPMC opened at $89.59 on Wednesday. The firm has a 50 day simple moving average of $99.49 and a 200-day simple moving average of $93.99. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market cap of $5.73 billion, a PE ratio of -82.95 and a beta of 0.58. Blueprint Medicines Co. has a 1-year low of $80.68 and a 1-year high of $121.90.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Recommended Stories
- Five stocks we like better than Blueprint Medicines
- 3 Best Fintech Stocks for a Portfolio Boost
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Must-Own Stocks to Build Wealth This Decade
- P/E Ratio Calculation: How to Assess Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.